Beam Therapeutics Inc. income statement BEAM

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Beam Therapeutics Inc. reported revenue of $139.7 million, up 120.0% from the year before. It recorded a net loss of $80.0 million. The operating loss came to $383.7 million, an operating margin of -274.6%. Diluted earnings per share were -$0.81. Over the twelve months ended Sep 30, 2026, revenue was $146.6 million and the net loss was $108.4 million. Across the 6 fiscal years shown, revenue grew from $24,000 in fiscal 2020 to $139.7 million in fiscal 2025, about 466.3% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Revenue
147
+163.3%
140
+120.0%
64
-83.2%
378
+520.0%
61
+17.5%
52
+215916.7%
0
Research and development
409
-0.7%
410
+11.4%
368
-16.0%
437
+40.4%
312
-19.5%
387
+275.2%
103
Selling, general and administrative
130
+18.1%
114
+2.1%
112
-4.5%
117
+33.0%
88
+53.4%
57
+93.3%
30
Operating income
-393
+15.8%
-384
+7.7%
-416
-135.5%
-176
+47.9%
-338
+13.8%
-392
-195.6%
-133
Other income (expense)
284
+437.3%
304
+681.4%
39
-14.3%
45
-42.1%
78
+258.7%
22
—
Pretax income
—
-80
+78.8%
-377
-187.2%
-131
+49.6%
-260
—
—
Income tax
0
0
-100.0%
0
-97.1%
1
-59.9%
3
0
0
Net income
-108
+73.8%
-80
+78.8%
-377
-184.3%
-133
+54.2%
-289
+22.0%
-371
-90.5%
-195
Basic EPS
-1.04
+76.3%
-0.81
+82.3%
-4.58
-166.3%
-1.72
+58.4%
-4.13
+28.4%
-5.77
—
Diluted EPS
-1.04
+76.3%
-0.81
+82.3%
-4.58
-166.3%
-1.72
+58.4%
-4.13
+28.4%
-5.77
—
Weighted average shares, basic
104
+10.6%
99
+20.2%
82
+6.7%
77
+10.2%
70
+9.0%
64
—
Weighted average shares, diluted
104
+10.6%
99
+20.2%
82
+6.7%
77
+10.2%
70
+9.0%
64
—
Other measures
Depreciation and amortization
22
+0.3%
22
+1.7%
22
+9.6%
20
+41.5%
14
+89.9%
7
+57.4%
5
EBITDA
-370
+16.6%
-361
+8.2%
-394
-151.6%
-156
+51.8%
-324
+15.8%
-385
-200.7%
-128
Margins
Operating margin
-267.68%
-274.57%
-654.25%
-46.73%
-555.61%
-757.01%
-553,166.67%
Pretax margin
—
-57.24%
-593.06%
-34.73%
-427.08%
—
—
Profit margin
-73.89%
-57.24%
-593.13%
-35.09%
-474.54%
-714.91%
-810,800.00%
EBITDA margin
-252.59%
-258.62%
-619.73%
-41.43%
-532.39%
-742.64%
-533,437.50%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BEAM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Large accelerated filer
SEC CIK
1745999
Former names
Beam Therapeutics Inc. (until Nov 3, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.